Trial Profile
An Open-Label Phase 1/2 Study to Investigate the Preliminary Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Dec 2022
Price :
$35
*
At a glance
- Drugs Aldoxorubicin (Primary) ; Ifosfamide; Mesna
- Indications Chondrosarcoma; Ewing's sarcoma; Gastrointestinal stromal tumours; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma
- Focus Adverse reactions
- Sponsors CytRx Corporation; LadRx Corporation
- 27 Jan 2022 Status changed from recruiting to completed.
- 07 Jun 2018 According to a CytRx Corporation media release, pooled data from this and other study (700214726) were presented at the American Society of Clinical Oncology 2018 Annual Meeting.
- 07 Jun 2018 Results presented in the CytRx Corporation media release.